Excelsior Biopharma Inc. (TPEX:6496)
Taiwan · Delayed Price · Currency is TWD 28.85
+0.05 (0.17%)
Jan 22, 2026, 1:30 PM CST
Excelsior Biopharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 859.77 | 861.91 | 771.56 | 671.76 | 1,338 | 1,444 | Upgrade | |
Revenue Growth (YoY) | 3.54% | 11.71% | 14.86% | -49.81% | -7.29% | -6.26% | Upgrade |
Cost of Revenue | 510.59 | 479.82 | 464.63 | 384.59 | 1,045 | 1,134 | Upgrade |
Gross Profit | 349.18 | 382.1 | 306.93 | 287.17 | 293.35 | 310.11 | Upgrade |
Selling, General & Admin | 408.78 | 377.21 | 324.57 | 277.82 | 241.65 | 211.96 | Upgrade |
Research & Development | 93.69 | 83.62 | 62.51 | 42.32 | 56 | 57.31 | Upgrade |
Operating Expenses | 503.44 | 463.07 | 388.06 | 316.47 | 302.12 | 268.63 | Upgrade |
Operating Income | -154.26 | -80.97 | -81.13 | -29.29 | -8.77 | 41.48 | Upgrade |
Interest Expense | -7.77 | -8.02 | -6.37 | -4.35 | -4.54 | -2.12 | Upgrade |
Interest & Investment Income | 2.32 | 3.42 | 5.24 | 4.17 | 0.41 | 0.43 | Upgrade |
Earnings From Equity Investments | 1.91 | 0.25 | - | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | -2.66 | -4.94 | -1.55 | -1.28 | 1.81 | 1.47 | Upgrade |
Other Non Operating Income (Expenses) | 5.88 | 2.87 | 1.86 | 3.68 | 0.9 | 4.04 | Upgrade |
EBT Excluding Unusual Items | -154.57 | -87.39 | -81.95 | -27.06 | -10.19 | 45.3 | Upgrade |
Gain (Loss) on Sale of Assets | -0.65 | - | - | - | - | 0 | Upgrade |
Other Unusual Items | 0.6 | 0 | - | 1.07 | 0.16 | - | Upgrade |
Pretax Income | -154.62 | -87.39 | -81.95 | -25.99 | -10.03 | 45.3 | Upgrade |
Income Tax Expense | 11.06 | 11.32 | 9.06 | 7.76 | 5.62 | 10 | Upgrade |
Net Income | -165.68 | -98.71 | -91.01 | -33.76 | -15.65 | 35.3 | Upgrade |
Net Income to Common | -165.68 | -98.71 | -91.01 | -33.76 | -15.65 | 35.3 | Upgrade |
Net Income Growth | - | - | - | - | - | -50.29% | Upgrade |
Shares Outstanding (Basic) | 46 | 46 | 46 | 46 | 47 | 47 | Upgrade |
Shares Outstanding (Diluted) | 46 | 46 | 46 | 46 | 47 | 49 | Upgrade |
Shares Change (YoY) | 0.10% | 0.42% | 0.15% | -1.42% | -5.56% | 5.12% | Upgrade |
EPS (Basic) | -3.59 | -2.14 | -1.98 | -0.74 | -0.34 | 0.76 | Upgrade |
EPS (Diluted) | -3.59 | -2.14 | -1.98 | -0.74 | -0.34 | 0.73 | Upgrade |
EPS Growth | - | - | - | - | - | -51.90% | Upgrade |
Free Cash Flow | -224.29 | -356.95 | -170.41 | -2.3 | 52.95 | 509.2 | Upgrade |
Free Cash Flow Per Share | -4.86 | -7.74 | -3.71 | -0.05 | 1.14 | 10.34 | Upgrade |
Dividend Per Share | - | - | - | - | - | 1.000 | Upgrade |
Gross Margin | 40.61% | 44.33% | 39.78% | 42.75% | 21.92% | 21.48% | Upgrade |
Operating Margin | -17.94% | -9.40% | -10.51% | -4.36% | -0.66% | 2.87% | Upgrade |
Profit Margin | -19.27% | -11.45% | -11.80% | -5.03% | -1.17% | 2.44% | Upgrade |
Free Cash Flow Margin | -26.09% | -41.41% | -22.09% | -0.34% | 3.96% | 35.27% | Upgrade |
EBITDA | -136.61 | -65.64 | -69.31 | -16.41 | 6.39 | 56.82 | Upgrade |
EBITDA Margin | -15.89% | -7.62% | -8.98% | -2.44% | 0.48% | 3.94% | Upgrade |
D&A For EBITDA | 17.65 | 15.33 | 11.82 | 12.88 | 15.15 | 15.34 | Upgrade |
EBIT | -154.26 | -80.97 | -81.13 | -29.29 | -8.77 | 41.48 | Upgrade |
EBIT Margin | -17.94% | -9.40% | -10.51% | -4.36% | -0.66% | 2.87% | Upgrade |
Effective Tax Rate | - | - | - | - | - | 22.07% | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.